Merck & Company Inc (MRK)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
NIVF
NewGenIvf Group Limited Class A Ordinary Shares
$0.69
-18.56%
HEALTHCARE · Cap: $1.77M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1391403% more annual revenue ($65.77B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 13.6%. NIVF trades at a lower P/E of 0.0x. NIVF earns a higher WallStSmart Score of 58/100 (C).
MRK
Hold50
out of 100
Grade: D+
NIVF
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for NIVF.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 79 in profit
Keeps 209 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of -349.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NIVF
The strongest argument for NIVF centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : NIVF
The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while NIVF is a mature play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
NIVF is growing revenue faster at 11.9% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NIVF scores higher overall (58/100 vs 50/100), backed by strong 209.0% margins and 11.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →NewGenIvf Group Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
NewGenIvf Group Limited (NIVF) is a prominent player in the reproductive health sector, specializing in innovative fertility solutions and advanced in vitro fertilization (IVF) services. With a commitment to enhancing success rates in assisted reproductive technology, NIVF is well-positioned to capitalize on the growing global demand for fertility treatments, supported by an extensive network of clinics and strategic partnerships. As the fertility services market continues to evolve, NIVF is positioned for considerable growth, dedicated to empowering individuals and couples in their journey to parenthood.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?